MAP2K1 and cancer: Several MEK1 mutations have been detected not only in primary (pre-treatment) cancers but also in recurrent cancers in patients treated with ERK pathway-targeted drugs (e.g., EGFR, Raf, or MEK inhibitors) (Supplementary Fig. 2a).